---
title: HCC1954 CDX Model - TD2 Precision Oncology
description: HCC1954 is a vital cell line in the realm of breast cancer research, specifically tailored to study HER2-positive tumors and their responses to targeted therapies.
image: https://td2inc.com/hubfs/Assets/GraphsFigures/hcc1954.jpg
---

×

 

[![td2-logo](https://td2inc.com/hubfs/td2-logo.png "td2-logo")](https://td2inc.com/?hsLang=en)

![Search Site](https://td2inc.com/hubfs/Assets/Icon/search-icon-1.png)

[![td2-logo](https://td2inc.com/hubfs/td2-logo.png "td2-logo")](https://td2inc.com/?hsLang=en)

![Search Site](https://td2inc.com/hubfs/Assets/Icon/search-icon-1.png)

# HCC1954 CDX Model

The HCC1954 cell line is derived from human HER2-positive breast cancer, a subtype characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2). This overexpression is often associated with aggressive tumor growth and a higher risk of recurrence. HCC1954 provides a crucial platform for elucidating the biology of HER2-positive tumors and for gauging the efficacy of targeted therapeutic strategies. This cell line exhibits many of the molecular features and genetic alterations typically observed in HER2-positive breast cancer patients, which enhances its applicability in preclinical research. Through in vitro and in vivo studies using HCC1954, insights can be gathered about the tumor’s growth dynamics, metastatic potential, and particularly its sensitivity and resistance mechanisms to HER2-targeted therapies. Researchers extensively utilize the HCC1954 model to understand the nuances of HER2-positive breast cancer and to test and refine therapeutic interventions, with a focus on optimizing anti-HER2 treatments.

## Model Details

**Cancer Location:** Mammary Fat Pad  
**Cancer Type:** HER2-Positive Breast Cancer  
**Model Name:** HCC1954  
**Mouse Strain:** NSG  
**Treatment Data Available:** Chemotherapy (Trastuzumab)

## HCC1954 Growth curves

![HCC1954 CDX Model](https://td2inc.com/hubfs/Assets/GraphsFigures/hcc1954.jpg)

Growth of orthotopic (MFP) HCC1954 in NSG mice (n=5)

### Request Additional CDX Model Data

## CONTACT US

## Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.

[Get Started Now](https://td2inc.com/contact-us/?hsLang=en)

[![td2-logo-footer](https://td2inc.com/hs-fs/hubfs/td2-logo.png?width=160&name=td2-logo.png)](https://td2inc.com/?hsLang=en)

Office  
13208 E. Shea Blvd,   
Suite 100   
Scottsdale, AZ 85259

Phone  
(602) 358-8300

Connect with us

- <https://www.linkedin.com/company/translational-drug-development/>
- <https://twitter.com/TD2_Oncology>

![td2-logo-footer](https://td2inc.com/hs-fs/hubfs/Assets/Logo/acclac-logo.png?width=139&name=acclac-logo.png)

© 2026 Translational Drug Development. All Rights Reserved. [Terms and Conditions](https://td2inc.com/terms-and-conditions?hsLang=en) | [Privacy Policy](https://td2inc.com/privacy-policy?hsLang=en)